Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

4-PBA and curcumin enhance protein expression of mutant ATP7B / News in Context

Feb. 16, 2010

New MR antagonists discovered at Bayer Schering Pharma

Feb. 15, 2010

Theracos identifies novel sodium/glucose cotransporter inhibitors

Feb. 15, 2010

Penwest initiates phase IIa trial of A-0001 in A3243G mitochondrial DNA point mutation

Feb. 15, 2010

Living Cell Technologies receives government grant for Diabecell

Feb. 12, 2010

Roche reports positive results from phase III clinical program of taspoglutide in diabetes

Feb. 11, 2010

Phase III mipomersen study meets primary endpoint in heFH

Feb. 11, 2010

Bristol-Myers Squibb reports the discovery of novel MCH-R1 antagonists

Feb. 11, 2010

Concert Pharmaceuticals describes novel DPP-IV inhibitors

Feb. 11, 2010

Xoma initiates phase IIb dose-finding XOMA-052 trial in type 2 diabetes

Feb. 10, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...